Delta 9 Cannabis Inc. operates as an integrated cannabis company. More Details
Mediocre balance sheet with limited growth.
Share Price & News
How has Delta 9 Cannabis's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: DN is less volatile than 75% of Canadian stocks over the past 3 months, typically moving +/- 4% a week.
Volatility Over Time: DN's weekly volatility (4%) has been stable over the past year.
7 Day Return
1 Year Return
Return vs Industry: DN underperformed the Canadian Pharmaceuticals industry which returned 51.7% over the past year.
Return vs Market: DN underperformed the Canadian Market which returned 28% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Delta 9 Cannabis's share price compared to the market and industry in the last 5 years?
Simply Wall St News
3 months ago | Simply Wall StDelta 9 Cannabis (TSE:DN) Is Carrying A Fair Bit Of Debt
7 months ago | Simply Wall StJohn Arbuthnot Is The Co-Founder of Delta 9 Cannabis Inc. (TSE:DN) And They Just Picked Up 1.0% More Shares
Is Delta 9 Cannabis undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate DN's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate DN's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: DN is unprofitable, so we can't compare its PE Ratio to the Canadian Pharmaceuticals industry average.
PE vs Market: DN is unprofitable, so we can't compare its PE Ratio to the Canadian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate DN's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: DN is good value based on its PB Ratio (1.5x) compared to the CA Pharmaceuticals industry average (2.8x).
How is Delta 9 Cannabis forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: DN is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: DN is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: DN is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: DN's revenue (25% per year) is forecast to grow faster than the Canadian market (5.5% per year).
High Growth Revenue: DN's revenue (25% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if DN's Return on Equity is forecast to be high in 3 years time
How has Delta 9 Cannabis performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: DN is currently unprofitable.
Growing Profit Margin: DN is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: DN is unprofitable, but has reduced losses over the past 5 years at a rate of 8.4% per year.
Accelerating Growth: Unable to compare DN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: DN is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (12.1%).
Return on Equity
High ROE: DN has a negative Return on Equity (-38.42%), as it is currently unprofitable.
How is Delta 9 Cannabis's financial position?
Financial Position Analysis
Short Term Liabilities: DN's short term assets (CA$31.4M) exceed its short term liabilities (CA$16.9M).
Long Term Liabilities: DN's short term assets (CA$31.4M) exceed its long term liabilities (CA$27.7M).
Debt to Equity History and Analysis
Debt Level: DN's debt to equity ratio (83.8%) is considered high.
Reducing Debt: DN had negative shareholder equity 5 years ago, but is now positive and has therefore improved.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Insufficient data to determine if DN has enough cash runway based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if DN has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is Delta 9 Cannabis's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate DN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate DN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if DN's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if DN's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of DN's dividend in 3 years as they are not forecast to pay a notable one for the Canadian market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
John Arbuthnot (31 yo)
Mr. John William Arbuthnot, IV, also known as John, has been Chief Executive Officer at Delta 9 Cannabis Inc. since October 31, 2017. Mr. Arbuthnot is Co-founder and Vice-President and Responsible Person i...
CEO Compensation Analysis
Compensation vs Market: John's total compensation ($USD329.81K) is above average for companies of similar size in the Canadian market ($USD164.57K).
Compensation vs Earnings: John's compensation has increased whilst the company is unprofitable.
Experienced Management: DN's management team is considered experienced (3.6 years average tenure).
Experienced Board: DN's board of directors are considered experienced (3.7 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: DN insiders have sold more shares than they have bought in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 15.1%.
Delta 9 Cannabis Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Delta 9 Cannabis Inc.
- Ticker: DN
- Exchange: TSX
- Founded: 2012
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: CA$43.118m
- Shares outstanding: 102.66m
- Website: https://www.delta9.ca
Number of Employees
- Delta 9 Cannabis Inc.
- P.O. Box 68096
- Osborne Village
- R3L 2V9
Delta 9 Cannabis Inc. operates as an integrated cannabis company. The company, through its subsidiary, Delta 9 Bio-Tech Inc., engages in the cultivation, processing, extraction, wholesale distribution, ret...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/07/25 00:26|
|End of Day Share Price||2021/07/23 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.